ALK and non-small cell lung carcinoma: Additional serum cytokines could also be screened for potential disease monitoring utility, including TGF-β, which has been demonstrated in a preclinical study to have abrogated tumour suppressive response in ALK + tumours [65], and other serum cytokines reported [22, 30] to be associated with NSCLC.